Trajectory of patient outcomes for those diagnosed with bronchiectasis is explored by Dr Metersky.
This is a video synopsis/summary of an Insights involving Mark Metersky, MD, FCCP, on the prognosis of bronchiectasis.
The prognosis varies based on severity, especially if treated aggressively early on. With treatment, most patients can have a normal life expectancy, though slow symptom progression often occurs. At initial evaluation, patients are counseled that bronchiectasis will likely persist lifelong as an annoyance rather than severely limiting. Evidence supports improved quality of life with specialty center care, though high-quality generalist care can replicate good outcomes.
The bronchiectasis severity index stratifies prognosis based on multiple factors like age, comorbidities, lung function, and chronic bacterial airway infection. Most patients have nonsevere disease without dramatically shortened survival. Death directly related to bronchiectasis is unusual.
Worse outcomes are predicted by chronic Pseudomonas airway infection and frequent exacerbations of 3 or more per year despite aggressive therapy. These patients tend to remain frequent exacerbators.
There are no FDA-approved bronchiectasis treatments. One nonapproved therapy, chronic low-dose macrolide antibiotics, can reduce exacerbation frequency, but most frequent exacerbators stay that way.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Surgery, Chemotherapy Considered Protective Survival Factors in Patients With OC, Liver Metastases
May 21st 2024Surgery and chemotherapy significantly improved both overall survival (OS) and cancer-specific survival (CSS) in patients with liver metastases originating from ovarian cancer (OC), who generally face a poor prognosis with a 5-year survival rate of less than 30%.
Read More
Unique Case: HCC With No Cirrhosis—and “Hidden” CLL/SLL
May 21st 2024A 77-year-old man had no risk factors for hepatocellular carcinoma (HCC), but he was nonetheless found to have it. Along the way, he was also diagnosed with previously undetected chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Read More